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group was 92% compared with 88% for the vancomycin group
(P < 0.0001). The lower costs for patients treated with linezolid
were attributable to the switch to oral therapy and earlier hos-
pital discharge. CONCLUSIONS: A higher cure rate in combi-
nation with lower overall treatment costs distinguishes linezolid
as a dominant therapy option compared with vancomycin in
patients with proven or suspected MRSA cSSTI.
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OBJECTIVES: To asses the cost-effectiveness of linezolid (600
mg IV, every 12h for 10 days), compared with vancomycin (1g
IV, every 12h for 10 days) for the treatment of ventilator-asso-
ciated pneumonia (VAP). METHODS: A decision model analy-
sis was performed from the National Health System perspective.
The primary outcome was the incremental cost-effectiveness of
linezolid in terms of cost per added QALY gained. The secondary
outcome was the marginal cost per year of life saved (YLS) gen-
erated by using linezolid. Clinical cure and survival rates 
estimates were derived from a retrospective analysis of two ran-
domized, double-blind trials comparing linezolid with van-
comycin. QALY were based on time-trade off study. Four subsets
of VAP patients were considered: all, with Gram-positive (GP),
with S. aureus (SA) and with methicillin-resistant SA (MRSA)
infection. Resources use and unit costs (2003€) were obtained
from Spanish VAP treatment guidelines and Spanish health costs
databases. Costs were evaluated for the acquisition of antibiotic
treatments, adverse reactions treatment, and antibiotic rescue,
extra diagnostic tests, the intensive care unit stay and medical
visits due to therapeutic failure. RESULTS: The additional QALY
and YLS per linezolid-treated patients were 0.392, 0.688, 0.606,
1.805 and 0.471, 0.829, 0.729, 2.175, respectively, compared
with that of vancomycin (all, GP, SA and MRSA VAP, respec-
tively). The additional cost per QALY gained obtained with 
linezolid was 1803.87€, 997.25€, 1149.00€ and 348.85€, respec-
tively. The additional cost per YLS obtained with linezolid was
1501.31€, 827.63€, 955.13€ and 289.51€, respectively. These
values are well below the acceptable threshold in Spain of
30,000€ per QALY/YLS gained. The sensitivity analyses con-
ﬁrmed the robustness of the base case analysis. CONCLU-
SIONS: According to this model, linezolid is a cost-effective
alternative to vancomycin for VAP patients in Spain, with an
additional cost per QALY/YLS gained below the acceptable
threshold for new therapies.
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OBJECTIVES: Hepatitis C (HCV) is a serious health problem
affecting around 170 million people worldwide. A considerable
health care burden is expected over the short to medium term,
because of earlier peaks in incidence rates and the presence of
undetected cases. The aim of the present study was to measure
resource use and direct costs associated with the management of
hepatitis C patients in a hospital-based Gastroenterology and
Hepatology Service (GAS). METHODS: A model of patient ﬂow
through the department was constructed, and expert opinion
was used to deﬁne relevant clinical sub-groups. Hospitalizations,
outpatient care and diagnostic tests for the group as a whole and
for each clinical sub-categoriy were calculated for the 4 month
study period using information from hospital records, depart-
ment protocols, and expert opinion. Unit costs were obtained
from the hospital administrative database. Antiviral treatments
were not included as they are not ﬁnanced from the GAS budget.
RESULTS: Data on use of resources and costs were obtained for
a total of 584 patients. The total cost of treating HCV patients
in the GAS for the study period was 600,343€ (1028€ per
patient). A total of 52% of these costs were attributable to diag-
nostic tests, 45% to hospitalization, and 3% to outpatient visits
two. The most costly clinical categories in overall terms were
post-transplant patients and chronic hepatitis patients, with total
costs for the 4-month study period of 136,185€ and 116,502€,
respectively. The two clinical categories with the highest per-
patient costs were pre-transplant decompensated cirrhosis and
hepatocarcinoma in decompensated cirrhosis, with per-patient
costs for the study period of 4731€ and 4498€, respectively. Hos-
pitalization was the principal cost driver in both instances. CON-
CLUSIONS: The study is useful in providing resource use and
cost information by clinical sub-categories which will help esti-
mate future resource use needs for these patients.
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OBJECTIVES: To evaluate lifetime clinical effectiveness and
cost-effectiveness of different antiviral treatment (AVT) strategies
in patients with chronic hepatitis C (CHC) using recent German
guidelines, that recommend basing drug dosage, intended treat-
ment duration and early stopping rules on the genotype of the
hepatitis C virus (HCV). METHODS: The German Hepatitis C
Model (GEHMO), a validated Markov model, was used to
project clinical events, life expectancy, QALYs, and lifetime costs
for the following AVT strategies: 1) no AVT (NoAVT); 2) Inter-
feron alfa-2b plus ribavirin for 48 weeks (IFN); 3) Peginterferon
alfa-2b plus ribavirin for 48 weeks (PEG); and 4) Peginterferon
alfa-2b plus ribavirin according to the German guidelines with
genotype-dependent AVT duration, dosing and early stoppage in
HCV-positive patients after 12 weeks (GUIDE). Incremental
cost-effectiveness ratios (ICER) were calculated from a societal
perspective. Clinical and drug utilization data were derived from
a clinical trial and from a survey of German hepatologists.
RESULTS: Combination therapy with peginterferon alfa-2b and
ribavirin (PEG or GUIDE) reduced the 20-year risk for decom-
pensated cirrhosis, hepatocellular carcinoma, liver transplanta-
tion, and liver-related death by more than 50%, compared to no
antiviral treatment. PEG increased life expectancy by 5.0 life
years and GUIDE increased life expectancy by 4.9 years com-
pared to NoAVT. GUIDE dominated IFN, so compared to
NoAVT, discounted ICERs were 1500€/QALY for GUIDE and
